


# CLAIMS

We claim :

1. A compound selected from those of formula (I) :




wherein

- ✓ R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> independently represent hydrogen, halogen or alkyl, alkoxy, hydroxy, alkylthio, mercapto, cyano, amino (optionally substituted by one or two alkyl), nitro, carboxy, alkoxycarbonyl, aminocarbonyl (optionally substituted by one or two alkyl) or carbamoyl,  
or, taken in pairs, form together with the carbon atoms to which they are bonded a phenyl ring or an aromatic heterocycle having from 5 to 7 ring members and containing from 1 to 3 hetero atoms selected from nitrogen, oxygen and sulphur,
- ✓ L<sub>1</sub> and L<sub>2</sub> each represents hydrogen or together form -CH<sub>2</sub>-CH<sub>2</sub>-,
- ✓ X<sub>1</sub>, attached at the 2 or 3 position of the aromatic ring, represents a bond, and in that case X<sub>2</sub> represents hydrogen, halogen, alkyl, alkoxy, hydroxy, nitro or cyano, or amino (optionally substituted by one or two alkyl),  
or,  
X<sub>1</sub> and X<sub>2</sub>, together with two adjacent carbon to which they are bonded in the 2, 3 or 4 position of the aromatic ring, form (C<sub>4</sub>-C<sub>7</sub>)cycloalkyl wherein one or two -CH<sub>2</sub>- of the cycloalkyl ring are optionally replaced by oxygen or NH (optionally substituted by alkyl) and wherein one carbon of the cycloalkyl ring is substituted by G,

- ✓  $X_3$  represents hydrogen, halogen, alkyl, alkoxy, hydroxy, nitro or cyano, or amino (optionally substituted by one or two alkyl),

- ✓ G represents a group selected from :



wherein :

- ✓ the broken lines indicate the optional presence of a double bond,
- ✓ Alk represents linear or branched ( $C_1$ - $C_6$ )alkylene wherein, when  $G_1$  or  $G_2$  contains imidazoline, the group Alk- is attached at the 2 position of the ring,
- ✓ n is 0 or 1,
- ✓  $T_3$  represents alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl,
- ✓  $T_4$  represents alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl,

wherein :

- the term "alkyl" denotes linear or branched group containing from 1 to 6 carbon,
- the term "alkoxy" denotes linear or branched alkyl-oxy containing from 1 to 6 carbon,
- the term "aryl" denotes phenyl, naphthyl or biphenyl,


- the term "heteroaryl" denotes an aromatic monocyclic group, or a bicyclic group in which at least one of the rings is aromatic, each group containing from 5 to 11 ring members and from 1 to 5 hetero atoms selected from nitrogen, oxygen and sulphur,
- the expression "optionally substituted" associated with aryl, arylalkyl, heteroaryl and heteroarylalkyl denotes that those groups are unsubstituted or substituted on the cyclic moiety by one or more halogen and/or alkyl, alkoxy, hydroxy, mercapto, alkylthio, cyano, amino (optionally substituted by one or two alkyl), nitro, carboxy, alkoxy carbonyl, aminocarbonyl (optionally substituted by one or two alkyl) or carbamoyl, wherein heteroaryl and heteroarylalkyl may in addition be substituted by oxo,

enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

2. Compounds of claim 1, wherein  $L_1$  and  $L_2$  each represents hydrogen, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.
3. Compounds of claim 1, wherein  $L_1$  and  $L_2$  together form  $-CH_2-CH_2-$ , enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.
4. Compounds of claim 1, wherein  $R_1$  and  $R_4$  each represents hydrogen, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.
5. Compounds of claim 1, wherein  $R_2$  and  $R_3$  are selected from halogen and alkyl, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

6. Compounds of claim 1, wherein  $X_1$  is attached at the 2 position of the phenyl ring, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.
7. Compounds of claim 1, wherein  $X_1$  represents a bond and  $X_2$  represents halogen or alkyl or alkoxy, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.
8. Compounds of claim 1, wherein  $X_3$  represents hydrogen, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.
9. Compounds of claim 1, wherein  $R_3$  and  $R_4$  together with carbon to which they are bonded form a phenyl ring and  $L_1$  and  $L_2$  together form  $-\text{CH}_1-\text{CH}_2-$ , enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

10. Compounds of claim 1, wherein G is selected from :



wherein  $T'_3$  will be more especially optionally substituted heteroaryl or optionally substituted heteroarylalkyl, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

11. Compounds of claim 1, wherein  $X_1$  and  $X_2$ , together with two carbon in the 2 and 3 position of the aromatic ring to which they are bonded, form  $(\text{C}_4-\text{C}_7)$ cycloalkyl, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base.

12. Compound of formula (I) that is *N*-(3-chloro-4-methylphenyl)-*N'*-{3-[4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-1-piperazinyl]phenyl}urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base

5 13. Compound of formula (I) that is *N*-[4-chloro-3-(4,5-dihydro-1*H*-imidazol-2-ylamino)phenyl]-*N'*-(3-chloro-4-methylphenyl)urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base

10 14. Compound of formula (I) that is *N*-(3-chloro-4-methylphenyl)-*N'*-[2-(1*H*-imidazol-4-yl)-indan-5-yl]urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base

15 15. Compound of formula (I) that is *N*-{3-[4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-1-piperazinyl]phenyl}-*N'*-(3,4-dimethylphenyl)urea, enantiomers and diastereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base

16. A method for treating an animal of human living body afflicted with a disease requiring as dual  $\alpha_2/5$ -HT<sub>2c</sub> antagonist comprising the step of administering to the living body an amount of a compound of claim 1 which is effective for alleviation of said condition.

20 17. A pharmaceutical composition comprising useful in the claim 16 method comprising as active ingredient one compound according to claim 1 in combination with one or more pharmaceutically acceptable, excipients or vehicles.